Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapyProactive Investors • 09/02/21
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer TreatmentBusiness Wire • 09/02/21
Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQGlobeNewsWire • 08/20/21
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tesla, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 08/18/21
Tiziana Life Sciences: Peer reviewed scientific article underscores the potential of monoclonal antibody nasal spray as a take-home Covid treatmentProactive Investors • 08/17/21
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in BrazilGlobeNewsWire • 08/17/21
Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor SummitNewsfile Corp • 08/16/21
Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences LimitedGlobeNewsWire • 07/02/21
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET todayGlobeNewsWire • 06/30/21
Tiziana Life Sciences pulls the trigger on phase II Covid trial after appointing a contract research groupProactive Investors • 06/23/21
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal AntibodyGlobeNewsWire • 06/23/21
Tiziana Life Sciences seeks UK funding for 'take-home' nasal COVID-19 treatmentProactive Investors • 06/17/21
Tiziana Responds to UK Call for Development of Innovative ‘Take Home' Treatments for COVID-19 DiseaseGlobeNewsWire • 06/17/21
Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General MeetingGlobeNewsWire • 06/02/21
US Investment bank repeats 'buy' and US$8 price target on Tiziana Life Sciences after flurry of positive newsProactive Investors • 05/28/21
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMSProactive Investors • 05/27/21
Tiziana Life's Foralumab Induces Immunomodulation, Anti-Inflammatory Effects In Early-Stage StudyBenzinga • 05/26/21